EIC Transition for the development of a novel precision gene therapy for brain tumors
| Reference number | |
| Coordinator | Sox Therapeutics AB |
| Funding from Vinnova | SEK 298 972 |
| Project duration | June 2025 - September 2025 |
| Status | Ongoing |
| Venture | Global cooperation 2025 |
| Call | Planning grant for international proposal 2025 |
Important results from the project
The project achieved its goal of preparing a complete EIC Transition application, titled “Translating SOX01: a Novel AAV-Based Precision Gene Therapy for Resistant Brain Tumors”. It includes regulatory roadmap, therapy development, IP, and business strategy. Important networks were built with regulatory, clinical, and commercial experts, strengthening the project’s path towards clinical application.
Expected long term effects
The project may lead to new treatment options for glioblastoma by targeting therapy-resistant cells and using biomarker-based diagnostics. In the long term, this could improve patient survival, optimize healthcare resources, and strengthen Swedish research and innovation in precision medicine.
Approach and implementation
The 12-week project, conducted from 25.06.2025 to 22.09.2025. The project was carried out as planned in four work packages: WP1 project planning, WP2 regulatory strategy, WP3 business and IP analysis, and WP4 application drafting was carried out by qualified grant consultancy. External experts provided quality assurance. The work followed the timeline and progressed as intended, with no major deviations. EIC Transition was submitted on 17th of September 2025.